And the results of that trial were published last August (2017): Title: Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial Authors: Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T Journal: Lancet 2017 Aug 3
By optimizing overall metabolic function, these drugs could create an environment more conducive to cognitive preservation
GLP-1s are powerful medications and should be prescribed only by medical professionals who have completed comprehensive medical assessments, including running labs, adds Zimmermann
Collectively, these results suggest that cinchonine is a potential GLP-1R agonist
The Morning You Take Your Shot Eat a high-protein, low-fat breakfast